Anemia normalization in patients with type 2 diabetes and chronic kidney disease: Results of the NEPHRODIAB2 randomized trial

Journal of Diabetes and its Complications

Volumn 25, Issue 4, 2011, Pages 237-243

  Villar, Emmanuel ^a   Lièvre, Michel ^b,c   Kessler, Michèle ^d   Lemaître, Vincent ^e   Alamartine, Eric ^f   Rodier, Michel ^g   François, Maud ^h   Zaoui, Philippe ⁱ   Moranne, Olivier ^j   Choukroun, Gabriel ^k   Guerraoui, Abdallah ^l   Jolivot, Anne ^m   Janin, Gérard ⁿ   Branger, Bernard ^g   Heng, Anne Elisabeth ^o   Boudray, Catherine ^p   Bissery, Alvine ^b   Rabilloud, Muriel ^b,c   Pouteil Noble, Claire ^a,c  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

^e CENTRE HOSPITALIER DE VALENCIENNES   (France)

^f UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^g NÎMES UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF TOURS   (France)

ⁱ Centre Hospitalier et Universitaire de Grenoble   (France)

^j LILLE UNIVERSITY HOSPITAL   (France)

^k AMIENS UNIVERSITY HOSPITAL   (France)

^l Centre Hospitalier de Vichy   (France)

^m EDOUARD HERRIOT HOSPITAL   (France)

ⁿ Centre Hospitalier de Macon   (France)

^o UNIVERSITÉ CLERMONT AUVERGNE   (France)

^p Centre Hospitalier de Bourg en Bresse   (France)

more..

Author keywords

Anemia; Chronic kidney disease; Erythropoiesis stimulating agent; Glomerular filtration rate; Type 2 diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HEMOGLOBIN; HEMOGLOBIN A1C; IRON;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36;

AGED; ANEMIA; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DRUG COSTS; DRUG MONITORING; ERYTHROPOIETIN; FEMALE; FRANCE; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 79959968580     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2011.03.003     Document Type: Article

References (33)

1. Alexander M., Kewalramani R., Agodoa I., and Globe D. Association of anemia correction with health related quality of life in patients not on dialysis Current Medical Research and Opinion 23 2007 2997 3008
2. Beauvieux M.C., Le Moigne F., and Lasseur C. New predictive equations improve monitoring of kidney function in patients with diabetes Diabetes Care 30 2007 1988 1994 (Pubitemid 47219405)
3. Beckman J.A., Creager M.A., and Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management JAMA 287 2002 2570 2581 (Pubitemid 34517204)
4. Brenner B.M., Cooper M.E., and de Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy New England Journal of Medicine 345 2001 861 869
5. Casadevall N., Nataf J., and Viron B. Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin New England Journal of Medicine 346 2002 469 475 (Pubitemid 34441737)
6. Chudleigh R.A., Dunseath G., and Evans J.N. How reliable is estimation of glomerular filtration rate at diagnosis of type 2 diabetes? Diabetes Care 30 2007 300 305 (Pubitemid 46198334)
7. Chudleigh R.A., Dunseath G., and Peter R. Influence of body weight on the performance of glomerular filtration rate estimators in subjects with type 2 diabetes Diabetes Care 31 2008 47 49
8. Chudleigh R.A., Ollerton R.L., and Dunseath G. Performance of the revised '175' Modification of Diet in Renal Disease equation in patients with type 2 diabetes Diabetologia 51 2008 1714 1718
9. Drueke T.B., Locatelli F., and Clyne N. Normalization of hemoglobin level in patients with chronic kidney disease and anemia New England Journal of Medicine 355 2006 2071 2084 (Pubitemid 44749316)
10. Estacio R.O., Jeffers B.W., Gifford N., and Schrier R.W. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes Diabetes Care 23 Suppl 2 2000 B54 B64
11. Foley R.N., and Collins A.J. End-stage renal disease in the United States: An update from the United States Renal Data System Journal of the American Society of Nephrology 18 2007 2644 2648 (Pubitemid 47531190)
12. Gouva C., Nikolopoulos P., Ioannidis J.P., and Siamopoulos K.C. Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial Kidney International 66 2004 753 760 (Pubitemid 38982019)
13. Hayashi T., Suzuki A., and Shoji T. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure American Journal of Kidney Diseases 35 2000 250 256 (Pubitemid 30070847)
14. Hörl W.H., Vanrenterghem Y., and Aljama P. OPTA: Optimal treatment of anaemia in patients with chronic kidney disease (CKD) Nephrology, Dialysis, Transplantation 22 Supp 3 2007 20 26
15. Jungers P., Choukroun G., Oualim Z., Robino C., Nguyen A.T., and Man N.K. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients Nephrology, Dialysis, Transplantation 16 2001 307 312 (Pubitemid 32123919)
16. Leehey D.J., Kramer H.J., Daoud T.M., Chatha M.P., and Isreb M.A. Progression of kidney disease in type 2 diabetes - Beyond blood pressure control: an observational study BMC Nephrol 6 2005 8
17. Levin A., and Rocco M. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target American Journal of Kidney Diseases 50 2007 471 530
18. Lewis E.J., Hunsicker L.G., and Clarke W.R. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes New England Journal of Medicine 345 2001 851 860
19. Macdougall I.C., Temple R.M., and Kwan J.T. Is early treatment of anaemia with epoetin alpha beneficial to predialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial Nephrology, Dialysis, Transplantation 22 2007 784 793 (Pubitemid 46351686)
20. Moranne O., Froissart M., and Rossert J. Timing of onset of CKD-related metabolic complications Journal of the American Society of Nephrology 20 2009 164 171
21. Orasanu G., and Plutzky J. The pathologic continuum of diabetic vascular disease Journal of the American College of Cardiology 53 Suppl 5 2009 35 42
22. Parving H.H., Lehneert H., and Bröchner-Mortensen J. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes New England Journal of Medicine 345 2001 870 878
23. Pfeffer M.A., Burdmann E.A., and Chen C.Y. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease New England Journal of Medicine 361 2009 2019 2032
24. Ravanan R., Spiro J.R., Mathieson P.W., and Smith R.M. Impact of diabetes on haemoglobin levels in renal disease Diabetologia 50 2007 26 31 (Pubitemid 46035848)
25. Rigalleau V., Lasseur C., and Raffaitin C. Progression-related bias in the monitoring of kidney function in patients with diabetes and chronic kidney disease Metabolism 57 2008 1428 1433
26. Ritz E., Laville M., and Bilous R.W. Target level for hemoglobin correction in patients with diabetes and CKD: Primary results of the Anemia Correction in Diabetes (ACORD) Study American Journal of Kidney Diseases 49 2007 194 207 (Pubitemid 46178405)
27. Rossert J., Levin A., and Roger S.D. Effect of early correction of anemia on the progression of CKD American Journal of Kidney Diseases 47 2006 738 750
28. Singh A.K., Szczech L., and Tang K.L. Correction of anemia with epoetin alpha in chronic kidney disease New England Journal of Medicine 355 2006 2085 2098 (Pubitemid 44749317)
29. Skyler J.S., Bergenstal R., and Bonow R.O. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE and VA diabetes trials. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association Journal of the American College of Cardiology 53 2009 298 304
30. Sorensen V.R., Mathiesen E.R., Heaf J., and Feldt-Rasmussen B. Improved survival rate in patients with diabetes and end-stage renal disease in Denmark Diabetologia 50 2007 922 929 (Pubitemid 46559250)
31. Stengel B., Billon S., and van Dijk P.C. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999 Nephrology, Dialysis, Transplantation 18 2003 1824 1833 (Pubitemid 37098555)
32. Thomas M.C., MacIsaac R.J., and Tsalamandris C. The burden of anaemia in type 2 diabetes and the role of nephropathy: A cross-sectional audit Nephrol DialTransplant 19 2004 1792 1797 (Pubitemid 38961389)
33. Villar E., Chang S.H., and McDonald S.P. Incidences, treatments, outcomes, and gender effect on survival in end-stage renal disease patients by diabetic status in Australia and New Zealand (1995-2005) Diabetes Care 30 2007 3070 3076 (Pubitemid 350255248)